Improved lumbar vertebral interbody fusion using rhOP-1: a comparison of autogenous bone graft, bovine hydroxylapatite (Bio-Oss), and BMP-7 (rhOP-1) in sheep.
METHODS
After disc removal and monosegmental instrumentation of the sheep lumbar spine, interbody fusion was compared for 6 months after administration of autogenous bone graft, hydroxylapatite, or rhOP-1.


OBJECTIVE
To determine whether the use of rhOP-1 or hydroxylapatite would improve on the intercorporal fusion achieved by autologous bone grafting.


BACKGROUND
Spinal fusion often fails or shows loss of correction despite large-scale conventional techniques using posterior and anterior access. Also, additional operations to obtain bone grafts are required, which increase morbidity and strain for the patient, but do not always provide bone with sufficient primary stability and high osteogenic potential.


METHODS
Vertebral fusion quality was examined by plain radiograph at 4-week intervals, by scintigraphy at 3 and 6 months, and by computed tomography scan, magnetic resonance imaging, biomechanical testing, and histologic evaluation.


RESULTS
All examination methods demonstrated superior fusion after administration of rhOP-1, with radiologic fusion apparent at 4 months. Autologous bone grafts eventually produced bony healing in most cases, albeit of a lower quality than with rhOP-1. Hydroxylapatite use led only to the formation of a tight pseudarthrosis.


CONCLUSIONS
The results indicate that rhOP-1 use is an appropriate method for improving interbody fusion in the sheep spine. In addition to offering the potential for improved bone healing, rhOP-1 use may permit less invasive surgery such as transpedicular fusion and the use of cages.
EuromedClinic, Fürth, Germany. mmagin@euromed.de
M N
MN
Magin
G
G
Delling
D000818:Animals; D001672:Biocompatible Materials / Q000627:therapeutic use; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000379:methods*; D017886:Durapatite / Q000627:therapeutic use*; D005260:Female; D007403:Intervertebral Disc / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D007405:Intervertebral Disc Displacement / Q000175:diagnosis / Q000601:surgery; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D008279:Magnetic Resonance Imaging; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D015203:Reproducibility of Results; D012756:Sheep; D013123:Spinal Fusion / Q000379:methods*; D014057:Tomography, X-Ray Computed; D016212:Transforming Growth Factor beta / Q000627:therapeutic use; D014182:Transplantation, Autologous; D014945:Wound Healing / Q000187:drug effects
D001672:Biocompatible Materials; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D018696:Neuroprotective Agents; D016212:Transforming Growth Factor beta; D017886:Durapatite